Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2609715 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL18292237 | 0.94 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL2115608 | 0.88 | HCAR2 (0.47) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL2115607 | 0.88 | HCAR2 (0.47) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL18288709 | 0.88 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL19701743 | 0.84 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1KEAP1NFE2L2HCAR2 | |
| SCHEMBL19701745 | 0.84 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1KEAP1NFE2L2HCAR2 | |
| SCHEMBL18288696 | 0.81 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL18288705 | 0.79 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1HPGDHCAR2L3MBTL1 | |
| SCHEMBL23241230 | 0.78 | CYP3A4 (0.34) | SMN1; SMN2ALDH1A1CYP3A4CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11246850-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-11129806-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11007166-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007167-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10959972-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20210023040-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-01-28 | — | — | US | disclosed |
| US-20200345679-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2020-11-05 | — | — | US | disclosed |
| US-20190125710-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20170354630-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC. | 2017-12-14 | — | — | US | disclosed |
| US-8778991-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129806-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | SMN1; SMN2 356/4885ALDH1A1 3424/4885HPGD 3393/4885 |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | SMN1; SMN2 2353/4885ALDH1A1 2050/4885HPGD 8/4885 |
| US-20190125710-A1 | Methods of Treating Multiple Sclerosis | FAH, FH, PML | SMN1; SMN2 356/4885ALDH1A1 3424/4885HPGD 3393/4885 |
| US-20210023040-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | SMN1; SMN2 356/4885ALDH1A1 3424/4885HPGD 3393/4885 |
| US-11007167-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | SMN1; SMN2 356/4885ALDH1A1 3424/4885HPGD 3393/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | SMN1; SMN2 2337/4885ALDH1A1 1970/4885HPGD 10/4885 |
| US-11007166-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | SMN1; SMN2 356/4885ALDH1A1 3424/4885HPGD 3393/4885 |
| US-11246850-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | SMN1; SMN2 356/4885ALDH1A1 3424/4885HPGD 3393/4885 |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | SMN1; SMN2 356/4885ALDH1A1 3424/4885HPGD 3393/4885 |
| US-10959972-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | SMN1; SMN2 356/4885ALDH1A1 3424/4885HPGD 3393/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | SMN1; SMN2 2353/4885ALDH1A1 2050/4885HPGD 8/4885 |
| US-20170354630-A1 | Methods of Treating Multiple Sclerosis | FAH, FH, PML | SMN1; SMN2 356/4885ALDH1A1 3424/4885HPGD 3393/4885 |
| US-20200345679-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | SMN1; SMN2 356/4885ALDH1A1 3424/4885HPGD 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.